NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC.

MONROE, LOUISIANA

FINANCIAL STATEMENTS

FOR THE YEAR ENDED

JUNE 30, 2022

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

7 F

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. JUNE 30, 2022

1

٦٢

CONTENTS

	PAGE
Independent Auditors' Report	1-4
Statement of Financial Position	5
Statement of Activities	б
Statement of Functional Expenses	7
Statement of Cash Flows	8
Notes to Financial Statements	9-17
SUPPLEMENTAL INFORMATION	
Schedule I - Schedule of Financial Position	18-19
Schedule II - Schedule of Activities	20-21
Schedule III - Schedule of Cash Flows	22-23
Schedule IV - Schedule of Functional Expenses	24-26
Schedule V - Schedule of Compensation, Benefits, and Other Payments to Agency Head or Chief Executive Officer	27
COMPLIANCE REPORTS	
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance	
with Government Auditing Standards	28-29
SCHEDULE OF FINDINGS AND QUESTIONED COSTS	30
SCHEDULE OF PRIOR YEAR FINDINGS	31

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

٦Ľ

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

VIOLET M. ROUSSEL, CPA, APC JAY CUTHBERT, CPA, APAC DAWN WHITSTINE, CPA, APC

PAM BATTAGLIA, CPA JOHN R. FORSELL, IV, CPA NICK RICHARDSON, CPA

ROWLAND H. PERRY, CPA-Retired CHARLES JOHNSON, JR., CPA-Retired



Certified Public Accountants 3007 Armand Street Monroe, Louisiana 71201 Telephone (318) 322-5156 Facsimile (318) 323-6331 Accounting & Auditing

 HUD Audits
 Non-Profit Organizations

- Governmental Organizations

Business & Financial Planning

Tax Preparation & Planning
 - individual & Partnership
 - Corporate & Fiduciary

Bookkeeping & Payroll Services

INDEPENDENT AUDITORS' REPORT

Board of Directors Northeast Louisiana Sickle Cell Anemia Foundation, Inc. Monroe, Louisiana

Report on the Financial Statements

We have audited the accompanying financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization), which comprise the statement of financial position as of June 30, 2022, and the related statements of activities, functional expenses, and cash flows for the year ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Northeast Louisiana Sickle Cell Anemia Foundation, Inc. as of June 30, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under in those standards are further described the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement. whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as involve collusion, forgery, fraud may intentional omissions, misrepresentations, override or the of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion

on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control. Accordingly, no such opinion is expressed.

- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The schedules I, II, III, IV and V on pages 18 through 27 are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated November 14, 2022 on our consideration of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the internal control over financial reporting or on compliance. That report is an integral part of an audit performed

in accordance with Government Auditing Standards in considering the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting and compliance.

Johnson Perry Roussel i Cashbort dens

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS Monroe, Louisiana November 14, 2022

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. STATEMENT OF FINANCIAL POSITION AS OF JUNE 30, 2022

<u>ASSETS</u>

<u>CURRENT ASSETS</u> Cash and Cash Equivalents Certificate of Deposit Unconditional Promises to Give - United Way Service Funding for Next Fiscal Year <u>TOTAL CURRENT ASSETS</u>	\$	35,069 17,095 19,000 71,164
FIXED ASSETS Land, Buildings, and Equipment, Net		116,783
NET FIXED ASSETS		116,783
TOTAL ASSETS	<u> </u>	187,947
LIABILITIES & NET ASSETS		
CURRENT LIABILITIES Deferred Revenue		141,290
TOTAL CURRENT LIABILITIES		141,290
TOTAL LIABILITIES		141,290
<u>NET ASSETS</u> Without Donor Restrictions With Donor Restrictions		22,451 24,206
TOTAL NET ASSETS		46,657
TOTAL LIABILITIES AND <u>NET ASSETS</u>	\$	187,947

See Independent Auditors' Report and Accompanying Notes.

- 5 -

lΓ

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. STATEMENT OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2022

SUPPORT AND REVENUE	<u>[</u>	<u>Vithout</u> Donor strictions		<u>th Donor</u> strictions		Total
<u>SUPPORT</u> Contributions Grants Other Income Net Assets Released from Restrictions	\$	42,369 - - 69,245	\$	- 88,245 - (69,245)	\$	42,369 88,245 -
TOTAL SUPPORT		111,614		19,000		130,614
<u>REVENUE</u> Special Events Interest Revenue		7,627 25		-		7,627 25
TOTAL REVENUE		7,652	<u></u>			7,652
TOTAL SUPPORT AND REVENUE	<u></u>	119,266		19,000	<u></u>	138,266
EXPENSES						
PROGRAM SERVICES		59,723			, <u></u>	59,723
SUPPORTING SERVICES Management & General		59,254				59,254
TOTAL SUPPORTING SERVICES		59,254	** /-2	<u> </u>		59,254
TOTAL FUNCTIONAL EXPENSES		118,977			<u></u>	118,977
Change in Net Assets		289		19,000		19,289
NET ASSETS AT BEGINNING OF YEAR		22,162	<u></u>	5,206		27,368
NET ASSETS AT END OF YEAR	\$	22,451	\$	24,206	\$	46,657

See Independent Auditors' Report and Accompanying Notes.

- 6 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

7 F

1

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. STATEMENT OF FUNCTIONAL EXPENSES FOR THE YEAR ENDED JUNE 30, 2022

		neral and ninistrative	Program		Total
Personnel Costs	•				
Salaries and Wages	\$	24,738	\$	29,041	\$ 53,779
Payroll Taxes and Other Fringe Benefits		1,906		2,237	4,143
Total Personnel Costs		26,644		31,278	 57,922
Other Expenses					
Advertising		-		-	-
Automobile Expense		88		104	192
Bank Service Charges		1		1	2
Depreciation Expense		4,798		5,633	10,431
Insurance		1,515		1,778	3,293
Interest		23		27	50
Maintenance		709		833	1,542
Office Expense		4,227		4,962	9,189
Other Program Expense		2,258		2,651	4,909
Postage and Delivery		86		102	188
Printing and Publication		120		140	260
Professional Fees		12,090		-	12,090
Repairs and Maintenance		1,539		1,806	3,345
Specific Assistance to Individuals		-		4,356	4,356
Storage		269		316	585
Telephone		-		-	-
Travel		-		-	-
Utilities		4,887	· · · · · · · · · · · · · · · · · · ·	5,736	 10,623
TOTAL EXPENSES	\$	59,254	\$	59,723	\$ 118,977

See Independent Auditors' Report and Accompanying Notes.

- 7 -

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. STATEMENT OF CASH FLOWS FOR THE YEAR ENDED JUNE 30, 2022

CASH FLOWS FROM OPERATING ACTIVITIES; Change in Net Assets Adjustments to Reconcile Change in Unrestricted Net	\$ 19,289
Assets to Net Cash Provided by Operating Activities Depreciation and Amortization	10,431
(Increase) Decrease in: Unconditional Promises to Give Increase (Decrease) in:	(19,000)
Accrued Liabilities	1,287
NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES	12,007
CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of Fixed Assets Gain on Investments	
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	(25)
CASH FLOWS FROM FINANCING ACTIVITIES: Payments on Line of Credit	. –
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	0
NET INCREASE (DECREASE) IN CASH	11,982
CASH AT BEGINNING OF PERIOD	23,087
CASH AT END OF PERIOD	\$ 35,069
Interest Paid Income Taxes Paid	50 0

See Independent Auditors' Report and Accompanying Notes.

- 8 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

71

NOTE 1 - <u>NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING</u> <u>POLICIES</u>:

Nature of Activities

The Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (the Foundation) is a private nonprofit organization domiciled in the State of Louisiana at Monroe, Louisiana. The Foundation is recognized as a tax-exempt (non-profit) organization under section 501(c)(3) of the Internal Revenue Service Code. The Foundation is supported primarily through state and private grants, contributions and donations from members, and fundraisers. The objective of the Foundation is primarily to provide services to persons born with sickle cell anemia, a hereditary disorder. Such services include educational programs, patient assistance programs, genetic counseling, research, and social services. A Board of Directors consisting of fifteen (15) members governs the Foundation. The Board Members receive no compensation.

Method of Accounting

The financial statements have been prepared on the accrual method of accounting and in conformity with the standards promulgated by the American Institute of Certified Public Accountants in its Audit and Accounting Guide for Not-for-Profit Organizations.

Basis of Presentation

The financial statements have been prepared in accordance with U.S generally accepted accounting principles ("US GAAP"), which require the Foundation to report information regarding its financial position and activities according to the following net asset classifications:

Net Assets without donor restrictions: Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Foundation. These net assets may be used at the discretion of the Foundation and the board of directors.

NOTE 1 - <u>NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING</u> POLICIES: (Continued)

Basis of Presentation (Continued)

Net Assets with donor restrictions: Net assets subject to stipulations imposed by donors, and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of the Foundation or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity. Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the statement of activities.

Promises to Give and Contributions

Contributions are recognized when the donor makes a promise that the Foundation is, in substance, to qive to unconditional. Contributions that are restricted by the donor are reported as increases in net assets without donor restrictions if the restrictions expire in the fiscal year in which the contributions are recognized. All other donorrestricted contributions are reported as increases in net assets with donor restrictions depending on the nature of the restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

Revenue Recognition

Revenue from Exchange Transactions: The Foundation recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. The Foundation records the following exchange transaction revenue in its statements of activities and changes in net assets for the year ending June 30, 2022:

NOTE 1 - NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Revenue Recognition (Continued)

Special Fundraising Event Revenue

The Foundation conducts special events in which a portion of the gross proceeds paid by the participant represents payment for the direct cost of the benefits received by the participant at the event-the exchange component, and a portion represents a contribution to the Foundation. Unless a verifiable objective means exists to demonstrate the fair value of meals and entertainment otherwise. provided at special events is measured at the actual cost the Foundation. The contribution component is the to excess of the gross proceeds over the fair value of the direct donor benefit. The direct costs of the special events, which ultimately benefit the donor rather than the Foundation, are recorded as costs of direct donor benefits in the (consolidated) statement of activities and changes in net assets. The performance obligation is delivery of the event, which is usually accompanied by a presentation. The event fee is set by the Foundation. FASB ASU 2014-09 requires allocation of the transaction price to the performance obligation(s). Accordingly, the Foundation separately in presents its statement of activities and changes in net assets or notes to financial statements the exchange contribution and components of the gross proceeds from special events. Special event fees collected by the Foundation in advance of its delivery are initially recognized as liabilities revenue) recognized (deferred and as special event revenue after delivery of the event. For special event fees received before year-end for an event to occur after year-end, the Foundation follows AICPA guidance where the inherent contribution is conditioned on the event taking place and is therefore treated as a refundable advance along with the exchange component.

NOTE 1 - <u>NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING</u> POLICIES: (Continued)

Public Support and Revenue

Grants and other contributions of cash and other assets are reported as support with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, stipulated time when а restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Contributions received with donor-imposed restrictions that are met in the same year in which the contributions are received are classified as contributions without donor restrictions.

Contributions of donated noncash assets are recorded at their fair values in the period received. Contributions of donated services that created or enhance nonfinancial assets or that require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation, are recorded at their fair values in the period received.

The accounting and reporting of grants is determined by the underlying substance of the transaction. A grant may be accounted for as contribution, an exchange transaction, or a combination of the two. If it is determined to be a contribution, a grant may be considered a conditional or an unconditional grant.

Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

NOTE 1 - <u>NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING</u> POLICIES: (Continued)

Income Taxes

The Foundation is exempt from federal income taxes under Section 501(c)(3)of the Internal Revenue Code. The Foundation believes that it has appropriate support for any tax provisions taken, and as such, does not have any uncertain tax positions that are material to the financial statements. The Foundations' Federal Return of Organization Exempt from Income Tax (form 990) for the years ended June 30, 2019, 2020, 2021, and 2022 are subject to examination by the TRS.

Advertising

The Foundation expenses advertising costs as they are incurred. For the year ended June 30, 2022, advertising expense was immaterial.

Reserve for Bad Debts

Accounts receivable are reviewed by management for bad debts monthly and it has been determined that there is no requirement for an allowance for doubtful accounts as of June 30, 2022.

Donated Services - Volunteers

No amounts have been reported in the financial statements for donated goods and services because no objective basis is available to measure the value of such services. Board members receive no compensation for services provided.

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Foundation considers all unrestricted highly liquid investments with an original maturity of three months or less to be cash equivalents. Fair value approximates carrying amounts.

NOTE 1 - <u>NATURE OF ACTIVITIES AND SUMMARY OF SIGNIFICANT ACCOUNTING</u> POLICIES: (Continued)

Depreciation

The Foundation follows the practice of capitalizing, at cost, all expenditures for fixed assets in excess of \$5,000. Depreciation is computed on a straight-line basis over the useful lives of the assets generally as follows:

Building and Improvements	30 Years
Furniture and Equipment	7 Years
Computers and Accessories	5 Years

Fair Value of Financial Instruments

The carrying amounts of cash, cash equivalents, investments, and notes payable are reported in the statement of financial position at approximate fair values because of the short maturity of those instruments.

NOTE 2 - NET ASSETS WITH DONOR RESTRICTIONS:

The donor restrictions on net assets for the year ended June 30, 2022 of \$5,206 relate to Walkathon funding and \$19,000 relate to United Way funding for the next year.

NOTE 3 - PROPERTY AND EQUIPMENT:

Property and equipment consisted of the following at June 30, 2022:

Furniture and Equipment	7/01/2021 27,585	Additions -	Deletions (645)	<u>6/30/2022</u> 26,940
Building	212,444	-	-	212,444
Vehicle	20,907	-	-	20,907
Less Accumulated				
Depreciation	(134,722)	(10,431)	645	(144,508)
Subtotal	126,214	(10, 431)	<u>645</u> -0-	115,783
Land	1,000		-0-	1,000
<u>Total</u>	127,214	(10, 431)	-0-	<u>116,783</u>

NOTE 3 - PROPERTY AND EQUIPMENT: (Continued)

Depreciation expense for the year ended June 30, 2022 was \$10,431.

NOTE 4 - COMPENSATED ABSENCES:

Compensated absences are absences for which employees will be paid, such as vacation, sick leave, and sabbatical leave. The Foundation has no policy for compensated absences. Therefore, those costs are not reflected in this report. However, for the purpose of this report the amounts are considered immaterial.

NOTE 5 - DEFERRED REVENUE:

Deferred revenue consists of the following:

United Way Funding 137,540 State of Louisiana Grant for Use in Next Fiscal Period 3,750

Total

141,290

NOTE 6 - FUNCTIONAL ALLOCATION OF EXPENSES:

The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefitted.

NOTE 7 - FUND DESCRIPTION:

For internal accounting purposes, the Foundation maintains the following separate funds:

General Fund

All assets over which the Board of Directors has discretionary control have been included in the General Fund.

- 15 -

NOTE 7 - FUND DESCRIPTION : (Continued)

United Way Fund

The United Way Fund is used to account for a grant from United Way of Northeast Louisiana.

Genetic Disease Fund

The Genetic Disease Fund is used to account for a state grant from the Louisiana Department of Health and Hospitals.

Walkathon Fund

The Walkathon Fund is used to account for proceeds from an annual fundraiser.

NOTE 8 - SUBSEQUENT EVENTS:

Events that occur after the balance sheet date but before the financial statements were issued must be evaluated for recognition or disclosure. The effects of subsequent events that provide evidence about conditions that existed after the balance sheet date require disclosure in the accompanying notes. Management evaluated the activity of the Foundation through November 14, 2022, the date the report was available for issue, and concluded that no subsequent events have occurred that would require recognition in the financial statements or disclosures in the notes to the financial statements.

NOTE 9 - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS:

The following reflects the Foundation's financial assets as of the balance sheet date of June 30, 2022, reduced by amounts not available for general use because of contractual or donor-imposed restrictions within one year of the balance sheet date.

NOTE 9 - LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS: (Continued)

Financial Assets at June 30, 2022 71,164

Less those unavailable for general expenditure within one year, due to:

Donor Restrictions

Financial assets availability to meet cash needs for general expenditure, within one year

In addition to financial assets available to meet general expenditures over the year, the Foundation anticipates covering its general expenditures using the income generated from dues, contributions, and fund-raising events.

24,206

46,958

NOTE 10 - FUND-RAISING ACTIVITIES:

Details of the special fund-raising events summarized on the statement of activities are as follows:

Banquet Fund-Raising Revenue	8,431
Direct Benefit Costs (Exchange Transaction)	(804)
Net (Contribution)	7,627

Total Net Fund-Raising Revenue 7,627

Other fund-raising costs were not material.

NOTE 11 - CONCENTRATION OF CREDIT RISK:

All cash funds are in institutions insured by an agency of the federal government.

- 17 -

SUPPLEMENTAL INFORMATION

•

SCHEDULE I

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FINANCIAL POSITION FOR THE YEAR ENDED JUNE 30, 2022

	Donor Restrictions	With	Donor Restr	ictions	
	Reperiedione	United	Genetic	10010115	
	General	Way	Disease	Walkathon	Total
	Fund	Fund	Fund	Fund	<u>All Funds</u>
		Assets			
urrent Assets					
Cash and Cash CD Unconditional	39,188	12,380	596		52,164
Promise to Give	-	19,000	-	-	19,000
Due from Other Funds		<u>125,160</u>	3,154	5,206	133,520
otal Current Assets	39,188	156,540	<u>3,750</u>	5,206	204,684
nvestments	_	-	-	<u></u>	-
hysical Properties					
Furniture and Equipment	26,940	_	_	_	26,940
Building	212,444		_	-	212,444
Vehicle	20,907	·	-		20,907
Accumulated Depreciation	(144,508)		_	_	(144,508
Land	1,000	_	with	~	1,000
otal Physical					
Properties	<u>116,783</u>				116,783
<u>Total Assets</u>	<u>155,971</u>	<u>156,540</u>	<u>3,750</u>	5,206	<u>321,467</u>
iabilities and Net ssets					
urrent Liabilities					
Accrued Liabilities	100 500	-	-	-	100 500
Due to Other Funds Deferred Revenue	133,520	137,540	3,750	_	133,520 141,290
Line of Credit	-				
otal Current					
Liabilities	133,520	137,540	3,750		274,810
ong-Term Liabilities					
otal Long-Term		0	0	~	~
Liabilities	-0-	-0-	-0-		-0-
Total Liabilities	133,520	137,540	3,750	-0-	274,810

See Independent Auditors' Report and Accompanying Notes.

~ 18 ~

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

٦٢

SCHEDULE I (Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FINANCIAL POSITION (CONTINUED) FOR THE YEAR ENDED JUNE 30, 2022

	Without				
	Donor				
	<u>Restrictions</u>	With	Donor Restr	ictions	
		United	Genetic		
	General	. Way	Disease	Walkathon	Total
	Fund	Fund	Fund	Fund	All Funds
	Liabilitie	es and Net	Assets		
Net Assets					
Without Donor					
Restrictions	22,451	-	-	-	22,451
With Donor					
Restrictions		19,000		5,206	24,206
<u>Total Net Assets</u>	_22,451	19,000	-0	5,206	46,657
Total Liabilities					
and Net Assets	<u>155,971</u>	<u>156,540</u>	<u>3,750</u>	<u>5,206</u>	<u>321,467</u>

See Independent Auditors' Report and Accompanying Notes.

- 19 -

SCHEDULE II

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF ACTIVITIES FOR THE YEAR ENDED JUNE 30, 2022

	Without Donor <u>Restrictions</u> General <u>Fund</u>	<u>With D</u> United Way Fund	Donor Restr Genetic Disease <u>Fund</u>	<u>ictions</u> Walkathon <u>Fund</u>	Total All Funds
<u>Changes in Net Assets W</u>		strictions	-		
· Contributions & Grants	44,752		-		44,752
Other Income	tree.	-	-		-
Investment Income	25	-		-	25
Special Events	7,627				7,627
Total Revenue and Gains Without Donor Restrictions	52,404	_0~	-0-	-0-	52,404
Net Assets Released fro Restrictions	m Restrictions				
Satisfied by Payments <u>Total Net Assets</u>	66,862				66,862
Released from Restrictions	66,862	_0_	<u>-0-</u>	<u>-0-</u>	66,862
Total Revenue Gains And Other Support Without Donor	· .				·
Restrictions	119,266	<u>-0-</u>	<u>-0-</u>	<u>-0-</u>	119,266
Expenses Program Expenses General and	59,723	-	-	-	59,723
Administrative Expenses	59,254	- King			59,254
Total Expenses	118,977	<u> </u>	<u>-0-</u>	-0-	118,977
Increase (Decrease) in Net Assets Without					
Donor Restrictions	289	<u>0-</u>	<u>-0-</u>	-0-	289

See Independent Auditors' Report and Accompanying Notes.

- 20 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

╧╧┙┝

					SCHEDULE II (Continued)		
NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF ACTIVITIES (CONTINUED) FOR THE YEAR ENDED JUNE 30, 2022							
	Without Donor <u>Restrictions</u> General <u>Fund</u>	United	onor Restri Genetic Disease Fund		Total <u>All Funds</u>		
Changes in Net Assets Wi Contributions Grants Net Assets Released from Restrictions Restrictions	th Donor Rest: - -	<u>rictions</u> 44,662	- 41,200	-	85,862		
Satisfied by Payments	_	(<u>25,662</u>)	(<u>41,200</u>)		(<u>66,862</u>)		
Increase (Decrease) in <u>Net Assets With</u> Donor Restrictions	-0-	-0-	0~		- 0 -		
Change in Net Assets	289	19,000	-		19,289		
<u>Net Assets at</u> Beginning of Year	22,162			5,206	27,368		
Net Assets at End of Year	22,451	_19,000	<u> </u>	<u>5,206</u>	<u>46,657</u>		

See Independent Auditors' Report and Accompanying Notes.

- 21 -

11

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

11

				SCH	HEDULE III
NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF CASH FLOWS FOR THE YEAR ENDED JUNE 30, 2022					
	Without Donor <u>Restrictions</u>		Donor Restr	ictions	
		United	Genetic		
	General	Way_	Disease	Walkathon	Total
	Fund	Fund	Fund	Fund	<u>All Funds</u>
<u>Operating Activities</u>					
Change in Net Assets	289	19,000	-	-	19,289
Adjustments to					
Reconcile Change in					
Net Assets to Net					
Cash Provided by					
Operating					
Activities:					
Provision for					
Depreciation	10,431			-	10,431
Decrease (Increase) in					
Due from Other Funds	_	1,004	(700)	-	304
Increase (Decrease) in					
Grants Receivable		-	_		_
Promise to Give	-	(19,000)	_	-	(19,000)
Accrued Liabilities			-	_	· · · · · · · · · · · · · · · · · · ·
Due to Other Funds	(304)	-		· _	(304)
Deferred Revenue	-	1,287		_	1,287
	·····	· <u> </u>			
Total Adjustments	10,127	(16,709)	(700)		(7,282)
-	<u></u>	<u> </u>	·/		·/
Net Cash Provided by					
Operating Activities	10,416	2,291	(<u>700</u>)	<u>-0-</u>	12,007

See Independent Auditors' Report and Accompanying Notes.

- 22 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

זר

SCHEDULE III (Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED JUNE 30, 2022

Investing Activities	Without Donor <u>Restrictions</u> General <u>Fund</u>	With J United Way Fund	Donor Restr Genetic Disease <u>Fund</u>	ictions Walkathon <u>Fund</u>	Total All Funds
Purchase of Fixed Assets Gain on Investment	(25)	· _		-	_ (25)
Net Cash Provided by Investing Activities	(<u>25</u>)	-0-		-0-	(25)
Financing Activities Payments on Line of Credit					-0-
Net Cash Provided by Financing Activities	-0-	-0-	- 0 -	-0-	- 0 -
<u>Net Increase</u> (Decrease) in Cash	10,391	2,291	(700)	_	11,982
<u>Cash and Cash</u> Equivalents at Beginning of Year	<u>11,702</u>	10,089	<u>1,296</u>		23,087
Cash and Cash Equivalents at End of Year	<u>22,093</u>	<u>12,380</u>	<u> </u>	<u> 0</u>	<u>35,069</u>

See Independent Auditors' Report and Accompanying Notes.

- 23 -

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

ור

SCHEDULE IV

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FUNCTIONAL EXPENSES JUNE 30, 2022

	Net Assets with Donor Restrictions <u>Released From Restriction</u> United Genetic				
	General Fund	Way Fund	Disease Fund	Walkathon Fund	Total All Funds
Program Expenses		· ·········			
Personnel Costs		15 500			
Salaries and Wages Payroll Taxes and		15,598	13,443	-	29,041
Other Fringe					
Benefits		1,124	1,113		2,237
Total Personnel Costs		16,722	14,556	-0-	31,278
Other Expenses					
Advertising		-	_		_
Automobile Expense	104		-	-	104
Bank Charges	1	-		-	1
Depreciation Expense	5,633	-	-	_	5,633
Insurance	1,778		-	-	1,778
Interest	27	-	—	-	27
Maintenance	833	~	-	-	833
Office Expense	4,962	· 🖬		-	4,962
Postage and Delivery	102		_		102
Printing and	140				1.40
Publication		-	~	-	
Program Expenses	2,651		_		2,651
Repairs and	1,806				1,806
Maintenance			-		
Specific Assistance to Individuals	4,356	_	_		4,356
Storage	316	_		-	316
Telephone	_			-	-
Travel		-	_	-	. –
Utilities	4,149	1,587			_5,736
Total Other Expenses	26,858	1,587		_0_	28,445
<u>Total Program Expenses</u>	26,858	18,309	14,556		59,723

See Independent Auditors' Report and Accompanying Notes.

-- 24 --

SCHEDULE IV (Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED) JUNE 30, 2022

	Net Assets with Donor Restrictions <u>Released From Restriction</u> United Genetic				
	General	Way	Disease	Walkathon	Total
	Fund	Fund	Fund	Fund	All Funds
<u>General and</u> Administrative Expenses	1 4114	Fund	<u>r unu</u>	Euna	All Fullus
Personnel Costs					
Salaries and Wages		_	24,738		24,738
Payroll Taxes and			24,150		24,730
Other Fringe					
Benefits	_	_	1 906		1 006
Denerres			1,906		<u>1,906</u>
Total Personnel Costs	hma		26,644	<u> </u>	26,644
Other Expenses					
Advertising	_	-		_	_
Automobile Expense	88				88
Bank Charges	1	_	-		1
Depreciation Expense	4,798		_	-	4,798
Interest Expense	23			_	23
Insurance	1,515		_	_	1,515
Maintenance	709	_	_	_	709
Office Expense	4,227		_		4,227
Other Program Expense	2,258	<u> </u>	_	_	2,258
Postage and Delivery	86	_	_	_	86
Printing and					
Publication	120	_	_		120
Professional Fees	6,090	6,000	_		12,090
Repairs and	.,	0,000			22/000
Maintenance	1,539	_	_	_	1,539
Storage	269	_	_	_	2,69
Telephone		-	_	_	2.07
Travel		_	_		_
Utilities	3,534	1,353		_	4,887
		<u> </u>			1001
Total Other Expenses	25,257	7,353	-0-	-0-	32,610

See Independent Auditors' Report and Accompanying Notes.

- 25 -

SCHEDULE IV (Continued)

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FUNCTIONAL EXPENSES (CONTINUED) JUNE 30, 2022

	Net Assets with Donor Restrictions Released From Restriction				
Totol Concursional	General Fund	United Way Fund	Genetic Disease <u>Fund</u>	Walkathon Fund	Total <u>All Funds</u>
Total General and Administrative Expenses	21,176	8,246	26,644		59,254
Total Functional Expenses	<u>52,115</u>	<u>25,662</u>	<u>41,200</u>	<u>-0-</u>	<u>118,977</u>

See Independent Auditors' Report and Accompanying Notes.

- 26 -

SCHEDULE V

NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF COMPENSATION, BENEFITS, AND OTHER PAYMENTS TO AGENCY HEAD OR CHIEF EXECUTIVE OFFICER FOR THE YEAR ENDED JUNE 30, 2022

AGENCY HEAD NAME/TITLE: DONNA THAXTON, EXECUTIVE DIRECTOR

Purpose	Amount Paid
Salary	30,402
Benefits-insurance	-0-
Benefits-retirement	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Benefits-other (describe)	-0-
Car allowance	-0-
Vehicle provided by government	
(enter amount reported on W-2)	-0-
Per diem	-0-
Reimbursements	571
Travel	-0-
Registration Fees	-0-
Conference travel	-0-
Housing	-0-
Unvouchered expenses (example:	
travel advances, etc.)	-0-
Special meals	-0-
Other - Training	-0-

See Independent Auditors' Report and Accompanying Notes.

- 27 -

COMPLIANCE REPORTS

r

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P.

VIOLET M. ROUSSEL, CPA, APC JAY CUTHBERT, CPA, APAC DAWN WHITSTINE, CPA, APC

PAM BATTAGLIA, CPA JOHN R. FORSELL, IV, CPA NICK RICHARDSON, CPA

ROWLAND H. PERRY, CPA-Retired CHARLES JOHNSON, JR., CPA-Retired



Certified Public Accountants 3007 Armand Street Monroe, Louisiana 71201 Telephone (318) 322-5156 Facsimile (318) 323-6331 Accounting & Auditing

HUD Audits
Non-Profit Organizations
Governmental Organizations

Business & Financial Planning
Tax Preparation & Planning

Individual & Partnership
Corporate & Fiduciary

Bookkeeping & Payroll Services

INDEPENDENT AUDITORS' REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors Northeast Louisiana Sickle Cell Anemia Foundation, Inc. Monroe, Louisiana

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc. (a nonprofit organization) which comprise the statement of financial position as of June 30, 2022, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated November 14, 2022.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Northeast Louisiana Sickle Cell Anemia Foundation, Inc.'s financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of non-compliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the organizations internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Johnson Revery Roussel & Cathbart dosp

JOHNSON, PERRY, ROUSSEL & CUTHBERT, L.L.P. CERTIFIED PUBLIC ACCOUNTANTS Monroe, Louisiana November 14, 2022


NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2022

Internal Control

There were no findings or questioned costs for the year ended June 30, 2022.

Compliance

There were no findings or questioned costs for the year ended June 30, 2022.



NORTHEAST LOUISIANA SICKLE CELL ANEMIA FOUNDATION, INC. SCHEDULE OF PRIOR YEAR FINDINGS JUNE 30, 2022

Internal Control

There were no findings or questioned costs for the year ended June 30, 2021.

Compliance

There were no findings or questioned costs for the year ended June 30, 2021.

- 31 -